{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T01:24:55Z","timestamp":1649121895485},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1007\/s11899-007-0031-1","type":"journal-article","created":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T17:40:20Z","timestamp":1191260420000},"page":"225-231","source":"Crossref","is-referenced-by-count":1,"title":["Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma"],"prefix":"10.1007","volume":"2","author":[{"given":"Constantine S.","family":"Tam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issa","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,2]]},"reference":[{"key":"31_CR1","first-page":"75","volume":"20","author":"S.J. Horning","year":"1993","unstructured":"Horning SJ: Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas. Semin Oncol 1993, 20:75\u201388.","journal-title":"Semin Oncol"},{"key":"31_CR2","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2004.07.170","volume":"22","author":"P.L. Zinzani","year":"2004","unstructured":"Zinzani PL, Pulsoni A, Perrotti A, et al.: Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004, 22:2654\u20132661.","journal-title":"J Clin Oncol"},{"key":"31_CR3","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P. McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825\u20132833.","journal-title":"J Clin Oncol"},{"key":"31_CR4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"M.S. Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, et al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352:441\u2013449.","journal-title":"N Engl J Med"},{"key":"31_CR5","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","volume":"102","author":"K. Besien Van","year":"2003","unstructured":"Van Besien K, Loberiza FRJ, Bajorunaite R, et al.: Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003, 102:3521\u20133529.","journal-title":"Blood"},{"key":"31_CR6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","volume":"31","author":"A.J. Peniket","year":"2003","unstructured":"Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al.: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003, 31:667\u2013678.","journal-title":"Bone Marrow Transplant"},{"key":"31_CR7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdg200","volume":"14","author":"C. Hosing","year":"2003","unstructured":"Hosing C, Saliba RM, McLaughlin P, et al.: Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin\u2019s lymphoma. Ann Oncol 2003, 14:737\u2013744.","journal-title":"Ann Oncol"},{"key":"31_CR8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2004.05194.x","volume":"127","author":"C.L. Toze","year":"2004","unstructured":"Toze CL, Barnett MJ, Connors JM, et al.: Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol 2004, 127:311\u2013321.","journal-title":"Br J Haematol"},{"key":"31_CR9","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2003.08.054","volume":"21","author":"P.J. Bierman","year":"2003","unstructured":"Bierman PJ, Sweetenham JW, Loberiza FRJ, et al.: Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin\u2019s lymphoma: a comparison with allogeneic and autologous transplantation\u2014The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003, 21:3744\u20133753.","journal-title":"J Clin Oncol"},{"key":"31_CR10","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","volume":"19","author":"K.W. Besien Van","year":"1997","unstructured":"Van Besien KW, de Lima M, Giralt SA, et al.: Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997, 19:977\u2013982.","journal-title":"Bone Marrow Transplant"},{"key":"31_CR11","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/sj.bmt.1704290","volume":"32","author":"C.M. Mandigers","year":"2003","unstructured":"Mandigers CM, Verdonck LF, Meijerink JP, et al.: Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003, 32:1159\u20131163.","journal-title":"Bone Marrow Transplant"},{"key":"31_CR12","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","volume":"16","author":"I.F. Khouri","year":"1998","unstructured":"Khouri IF, Keating M, Korbling M, et al.: Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817\u20132824.","journal-title":"J Clin Oncol"},{"key":"31_CR13","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","volume":"98","author":"I.F. Khouri","year":"2001","unstructured":"Khouri IF, Saliba RM, Giralt SA, et al.: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001, 98:3595\u20133599.","journal-title":"Blood"},{"key":"31_CR14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.exphem.2003.09.021","volume":"32","author":"I.F. Khouri","year":"2004","unstructured":"Khouri IF, Lee MS, Saliba RM, et al.: Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004, 32:28\u201335.","journal-title":"Exp Hematol"},{"key":"31_CR15","doi-asserted-by":"crossref","unstructured":"Khouri IF, Saliba RM, Hosing CM, et al.: Autologous stem cell (AUTO) vs non-myeloablative allogeneic transplantation (NMT) after high-dose rituximab (HD-R)-containing conditioning regimens for relapsed chemosensitive follicular lymphoma (FL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 48.","DOI":"10.1182\/blood.V106.11.48.48"},{"key":"31_CR16","doi-asserted-by":"crossref","unstructured":"Khouri IF, Lee MS, Saliba RM, et al.: Non-myeloablative allogeneic transplantation (NMT) with T-cell replete graft for relapsed chemosensitive follicular lymphoma (FL): Donor lymphocyte infusion (DLI) to convert stable mixed chimerism to full donor chimerism is not necessary in the absence of disease progression [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 3659.","DOI":"10.1182\/blood.V106.11.3659.3659"},{"key":"31_CR17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","volume":"12","author":"A. Demidem","year":"1997","unstructured":"Demidem A, Lam T, Alas S, et al.: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:177\u2013186.","journal-title":"Cancer Biother Radiopharm"},{"key":"31_CR18","first-page":"5137","volume":"61","author":"S. Alas","year":"2001","unstructured":"Alas S, Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin\u2019s lymphoma through inhibition of the interleukin 10 autocrine\/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001, 61:5137\u20135144.","journal-title":"Cancer Res"},{"key":"31_CR19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1046\/j.1365-2141.2001.03014.x","volume":"114","author":"N. Gaetano Di","year":"2001","unstructured":"Di Gaetano N, Xiao Y, Erba E, et al.: Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001, 114:800\u2013809.","journal-title":"Br J Haematol"},{"key":"31_CR20","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"D.G. Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA, et al.: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 1997, 90:2188\u20132195.","journal-title":"Blood"},{"key":"31_CR21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00002371-200211000-00002","volume":"25","author":"F.J. Hsu","year":"2002","unstructured":"Hsu FJ, Komarovskaya M: CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells. J Immunother (1997) 2002, 25:455\u2013468.","journal-title":"J Immunother (1997)"},{"key":"31_CR22","first-page":"289","volume":"16","author":"K.R. Schultz","year":"1995","unstructured":"Schultz KR, Paquet J, Bader S, HayGlass KT: Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995, 16:289\u2013295.","journal-title":"Bone Marrow Transplant"},{"key":"31_CR23","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","volume":"19","author":"S.M. O\u2019Brien","year":"2001","unstructured":"O\u2019Brien SM, Kantarjian H, Thomas DA, et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19:2165\u20132170.","journal-title":"J Clin Oncol"},{"key":"31_CR24","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","volume":"19","author":"J.C. Byrd","year":"2001","unstructured":"Byrd JC, Murphy T, Howard RS, et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001, 19:2153\u20132164.","journal-title":"J Clin Oncol"},{"key":"31_CR25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.bmt.1705027","volume":"36","author":"E. Kusumi","year":"2005","unstructured":"Kusumi E, Kami M, Kanda Y, et al.: Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 2005, 36:205\u2013213.","journal-title":"Bone Marrow Transplant"},{"key":"31_CR26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3324\/haematol.10924","volume":"92","author":"S. Vigouroux","year":"2007","unstructured":"Vigouroux S, Michallet M, Porcher R, et al.: Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007, 92:627\u2013634.","journal-title":"Haematologica"},{"key":"31_CR27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood-2003-05-1406","volume":"103","author":"R.D. Faulkner","year":"2004","unstructured":"Faulkner RD, Craddock C, Byrne JL, et al.: BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004, 103:428\u2013434.","journal-title":"Blood"},{"key":"31_CR28","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","volume":"12","author":"R. Rodriguez","year":"2006","unstructured":"Rodriguez R, Nademanee A, Ruel N, et al.: Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant 2006, 12:1326\u20131334.","journal-title":"Biol Blood Marrow Transplant"},{"key":"31_CR29","doi-asserted-by":"crossref","unstructured":"Van Besien K, Carreras J, Zhang MJ, et al.: Reduced intensity vs myeloablative conditioning for HLA matched sibling transplantation in follicular lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 656.","DOI":"10.1182\/blood.V106.11.656.656"},{"key":"31_CR30","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","volume":"100","author":"S.P. Robinson","year":"2002","unstructured":"Robinson SP, Goldstone AH, Mackinnon S, et al.: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002, 100:4310\u20134316.","journal-title":"Blood"},{"key":"31_CR31","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","volume":"104","author":"E. Morris","year":"2004","unstructured":"Morris E, Thomson K, Craddock C, et al.: Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004, 104:3865\u20133871.","journal-title":"Blood"},{"key":"31_CR32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/sj.leu.2403258","volume":"18","author":"J. Lundin","year":"2004","unstructured":"Lundin J, Porwit-MacDonald A, Rossmann ED, et al.: Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004, 18:484\u2013490.","journal-title":"Leukemia"},{"key":"31_CR33","doi-asserted-by":"crossref","unstructured":"Maris MB, Sandmaier BM, Storer B, et al.: Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1130.","DOI":"10.1182\/blood.V106.11.1130.1130"},{"key":"31_CR34","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2002.11.088","volume":"20","author":"K. Branson","year":"2002","unstructured":"Branson K, Chopra R, Kottaridis PD, et al.: Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002, 20:4022\u20134031.","journal-title":"J Clin Oncol"},{"key":"31_CR35","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1200\/JCO.2004.09.092","volume":"22","author":"M.P. Escalon","year":"2004","unstructured":"Escalon MP, Champlin RE, Saliba RM, et al.: Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin\u2019s lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004, 22:2419\u20132423.","journal-title":"J Clin Oncol"},{"key":"31_CR36","doi-asserted-by":"crossref","unstructured":"Khouri IF, Saliba RM, Hosing C, et al.: Efficacy and safety of yttrium 90 (90 Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin\u2019s lymphoma (NHL) [abstract]. Blood (ASH Annual Meeting Abstract) 2006, 108:Abstract 315.","DOI":"10.1182\/blood.V108.11.315.315"},{"key":"31_CR37","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2005.08.136","volume":"23","author":"F. Baron","year":"2005","unstructured":"Baron F, Maris MB, Sandmaier BM, et al.: Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005, 23:1993\u20132003.","journal-title":"J Clin Oncol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0031-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-007-0031-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0031-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T23:32:35Z","timestamp":1587943955000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-007-0031-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["31"],"URL":"https:\/\/doi.org\/10.1007\/s11899-007-0031-1","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}